潜在性結核検査市場：製品タイプ、検査タイプ、用途、エンドユーザー別-2025-2030年の世界予測

潜在性結核検査市場は、2024年には13億2,000万米ドルとなり、2025年には13億9,000万米ドル、CAGR 5.70％で成長し、2030年には18億4,000万米ドルに達すると予測されています。

急速に進化する今日のヘルスケア環境において、診断ソリューションの革新に対する重要なニーズは紛れもないものとなっています。潜伏結核検査は、早期発見とタイムリーな介入を可能にすることで、結核と闘う取り組みの最前線に立っています。本レポートでは、潜在性結核検査市場を詳細に概観し、公衆衛生と臨床におけるその重要性に注目します。近年、結核の潜伏型に対する意識の高まりと診断技術の進歩が相まって、ヘルスケア専門家による検出と管理への取り組み方が大きく変化しています。正確で効率的な検査法が登場したことで、市場は従来の手法から、より高い精度と迅速な納期を約束する、より洗練されたアッセイ法へと移行しつつあります。

この包括的な分析では、市場促進要因・課題、新技術の統合、業界を導く進化する規制の枠組みを探ります。業界の重要なシフトやセグメンテーションに関する洞察を網羅し、現在の市場情勢を俯瞰しています。アプリケーション分野、試験イノベーション、地域差を掘り下げることで、意思決定者や専門家にとって魅力的で権威ある視点を提供することを目的としています。

市場情勢を再定義する転換期

潜在性結核検査市場は、技術の進歩、規制当局の監視の強化、臨床医の期待の急速な変化などにより、変革的な進化を遂げつつあります。インターフェロンγ放出アッセイやツベルクリン皮膚テストなどのアッセイ技術の開発は、検査がより高感度で特異的であるだけでなく、より合理的でアクセスしやすくなることを保証し、変化を促しています。自動化、デジタルデータ統合、検体処理における革新は、業務効率を高め、所要時間を短縮し、検査室がより多くの量を一貫した精度で処理することを可能にしています。

さらに、患者の人口動態の変化と予防ヘルスケア戦略への関心の高まりが、市場の優先順位にさらなる影響を与えています。利害関係者は現在、既存の診断ワークフローにシームレスに統合し、臨床判断を強力にサポートするソリューションの採用を迫られています。政策改革や国際的な医療イニシアティブも市場力学の形成に不可欠な役割を果たしており、新しい検査手法の採用を後押ししています。この変革期は、研究主導の洞察と実臨床との統合によって特徴付けられ、それによって先進的な診断の恩恵がより広範な人々に行き渡ることを保証しています。サマリーをまとめると、潜在性結核検査の状況は、イノベーション、戦略的投資、そして進化するヘルスケアへの深い理解の融合によって再構築されつつあります。

包括的な分析による主要なセグメンテーションの洞察

潜在性結核検査市場を詳細に分析すると、その多面的なダイナミクスを理解する上で重要な多層的なセグメンテーションが明らかになります。この市場は、製品タイプ別、検査タイプ別、用途別、エンドユーザー別という複数のプリズムを通して分析されます。製品タイプ別では、機器、キット、試薬がそれぞれ異なる業務ニーズや性能指標に対応しています。検査タイプでは、インターフェロン・ガンマ放出アッセイとツベルクリン皮膚テストを区別しています。特に、インターフェロンγ放出アッセイ法は、化学発光法やELISA法などの技術に分類され、ツベルクリン皮膚テスト法は、皮内法と多穿刺法に分類されます。

市場セグメンテーションはさらなる洞察を提供し、市場が診断検査、調査、スクリーニング目的でどのように調整されているかを強調します。調査そのものは、新規検査開発とワクチン開発に細分化され、イノベーションとバリデーションの二重の役割が強調されています。スクリーニング用途は、日常的な健康診断の要件と、多様な人口動態を対象とする移民スクリーニングプロセスによって微妙に変化します。最後に、エンドユーザーセグメンテーションは、診断センター、病院検査室、公衆衛生局、研究機関における市場力学を捉えています。これらのセグメントを組み合わせることで、業界の詳細な地図が得られ、利害関係者は各セグメントの業務上のニュアンスを正確に理解することで、新たなニーズをピンポイントで捉え、製品を調整することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 移動診療所を通じて、農村部や医療サービスが行き届いていない地域への潜在性結核検査の普及が拡大
    • 免疫系を弱め、結核感染に対する感受性を高める疾患の増加
    • 潜在性結核感染に対するリスクのある人々とヘルスケア従事者の間での意識の高まり
  • 抑制要因
    • 高額な費用と限られた資金が潜在性結核検査のアクセシビリティと拡張に与える影響を分析する
  • 機会
    • 結核検査方法の技術的進歩により、スピード、精度、アクセス性が向上
    • 潜在性結核診断市場を強化する官民連携
  • 課題
    • 国や地域によって政府の政策や規制が一貫していない
• 市場セグメンテーション分析
  • 検査の種類：ツベルクリン皮膚検査の精度とアクセス性の向上に利用
  • エンドユーザー：高度な技術により病院の検査室で潜在性結核検査を採用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 潜在性結核検査市場：製品タイプ別

• 機器
• キット
• 試薬

第7章 潜在性結核検査市場テストタイプ別

• インターフェロンガンマ放出アッセイ（IGRA）
  • 化学発光
  • ELISA（酵素免疫測定法）
• ツベルクリン皮膚テスト（TST）
  • 皮内
  • マルチパンクチャー

第8章 潜在性結核検査市場：用途別

• 診断検査
• 調査
  • 新しいテスト開発
  • ワクチン開発
• スクリーニング
  • 健康診断
  • 入国審査

第9章 潜在性結核検査市場：エンドユーザー別

• 診断センター
• 病院の検査室
• 公衆衛生局
• 調査機関

第10章 南北アメリカの潜在性結核検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の潜在性結核検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの潜在性結核検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Beckman Coulter, Inc.
• Becton, Dickinson and Company（BD）
• Bio-Rad Laboratories, Inc.
• Biocare Medical, LLC
• bioMerieux SA
• Cepheid, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Eiken Chemical Co., Ltd.
• ElitechGroup SAS by Bruker Company
• F. Hoffmann-La Roche AG
• Fujifilm Holdings Corporation
• Hologic, Inc.
• Mabtech AB
• Meridian Bioscience, Inc.
• Oxford Immunotec Limited by PerkinElmer, Inc.
• Qiagen N.V.
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.
• Tosoh Bioscience, Inc.

LIST OF FIGURES

• FIGURE 1. LATENT TB TESTING MARKET MULTI-CURRENCY
• FIGURE 2. LATENT TB TESTING MARKET MULTI-LANGUAGE
• FIGURE 3. LATENT TB TESTING MARKET RESEARCH PROCESS
• FIGURE 4. LATENT TB TESTING MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL LATENT TB TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL LATENT TB TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL LATENT TB TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL LATENT TB TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 17. AMERICAS LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES LATENT TB TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 19. UNITED STATES LATENT TB TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. LATENT TB TESTING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 25. LATENT TB TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. LATENT TB TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL LATENT TB TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LATENT TB TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LATENT TB TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LATENT TB TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LATENT TB TESTING MARKET SIZE, BY KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LATENT TB TESTING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LATENT TB TESTING MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LATENT TB TESTING MARKET SIZE, BY ELISA (ENZYME-LINKED IMMUNOSORBENT ASSAY), BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LATENT TB TESTING MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LATENT TB TESTING MARKET SIZE, BY MULTIPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL LATENT TB TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL LATENT TB TESTING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL LATENT TB TESTING MARKET SIZE, BY NEW TEST DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL LATENT TB TESTING MARKET SIZE, BY VACCINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL LATENT TB TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL LATENT TB TESTING MARKET SIZE, BY HEALTH CHECK-UPS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL LATENT TB TESTING MARKET SIZE, BY IMMIGRATION SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL LATENT TB TESTING MARKET SIZE, BY DIAGNOSTIC CENTRES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL LATENT TB TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL LATENT TB TESTING MARKET SIZE, BY PUBLIC HEALTH DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL LATENT TB TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 60. CANADA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CANADA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CANADA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 63. CANADA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 64. CANADA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 65. CANADA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 66. CANADA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 67. CANADA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 71. MEXICO LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 72. MEXICO LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES LATENT TB TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 96. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 97. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 98. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 102. CHINA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. CHINA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 104. CHINA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 105. CHINA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 106. CHINA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 107. CHINA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 108. CHINA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 109. CHINA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 110. INDIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. INDIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 112. INDIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 113. INDIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 114. INDIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. INDIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 116. INDIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 117. INDIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. INDONESIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 119. INDONESIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 120. INDONESIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 121. INDONESIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 122. INDONESIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. JAPAN LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. JAPAN LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 128. JAPAN LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 129. JAPAN LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 130. JAPAN LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. MALAYSIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 135. MALAYSIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 136. MALAYSIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 137. MALAYSIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 138. MALAYSIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 142. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 143. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 144. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 145. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 146. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. SINGAPORE LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 151. SINGAPORE LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 152. SINGAPORE LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 153. SINGAPORE LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 154. SINGAPORE LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. SINGAPORE LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 158. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 161. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 162. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 166. TAIWAN LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 167. TAIWAN LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 168. TAIWAN LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 169. TAIWAN LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 170. TAIWAN LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 171. TAIWAN LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 174. THAILAND LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 175. THAILAND LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 176. THAILAND LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 177. THAILAND LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 178. THAILAND LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. THAILAND LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. VIETNAM LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 183. VIETNAM LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 184. VIETNAM LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 185. VIETNAM LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 186. VIETNAM LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. VIETNAM LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 191. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 192. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 193. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 194. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA LATENT TB TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 199. DENMARK LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 200. DENMARK LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 201. DENMARK LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 202. DENMARK LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 203. DENMARK LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 204. DENMARK LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 207. EGYPT LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 208. EGYPT LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 209. EGYPT LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 210. EGYPT LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 211. EGYPT LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 212. EGYPT LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. FINLAND LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 216. FINLAND LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 217. FINLAND LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 218. FINLAND LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 219. FINLAND LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. FINLAND LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 223. FRANCE LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 224. FRANCE LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 225. FRANCE LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 226. FRANCE LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 227. FRANCE LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 228. FRANCE LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 231. GERMANY LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 232. GERMANY LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 233. GERMANY LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 234. GERMANY LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 235. GERMANY LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. GERMANY LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 239. ISRAEL LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 240. ISRAEL LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 241. ISRAEL LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 242. ISRAEL LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 243. ISRAEL LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 244. ISRAEL LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 247. ITALY LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 248. ITALY LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 249. ITALY LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 250. ITALY LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 251. ITALY LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 252. ITALY LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 253. ITALY LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 254. ITALY LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 255. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 256. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 257. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 258. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 259. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 260. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 263. NIGERIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 264. NIGERIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 265. NIGERIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 266. NIGERIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 267. NIGERIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 268. NIGERIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 271. NORWAY LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 272. NORWAY LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 273. NORWAY LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 274. NORWAY LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 275. NORWAY LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 276. NORWAY LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 279. POLAND LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 280. POLAND LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 281. POLAND LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 282. POLAND LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 283. POLAND LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 284. POLAND LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 285. POLAND LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 286. POLAND LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 287. QATAR LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 288. QATAR LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 289. QATAR LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 290. QATAR LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 291. QATAR LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 292. QATAR LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 293. QATAR LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 294. QATAR LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 295. RUSSIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 296. RUSSIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 297. RUSSIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 298. RUSSIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 299. RUSSIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 300. RUSSIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 303. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 304. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 305. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 306. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 307. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 308. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 310. SAUDI ARABIA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 311. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 312. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 313. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 314. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 315. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 316. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 318. SOUTH AFRICA LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 319. SPAIN LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 320. SPAIN LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 321. SPAIN LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 322. SPAIN LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 323. SPAIN LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 324. SPAIN LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 325. SPAIN LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 326. SPAIN LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 327. SWEDEN LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 328. SWEDEN LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 329. SWEDEN LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 330. SWEDEN LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 331. SWEDEN LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 332. SWEDEN LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 333. SWEDEN LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 334. SWEDEN LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 335. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 336. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 337. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY INTERFERON GAMMA RELEASE ASSAYS (IGRAS), 2018-2030 (USD MILLION)
• TABLE 338. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY TUBERCULIN SKIN TEST (TST), 2018-2030 (USD MILLION)
• TABLE 339. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 340. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
• TABLE 341. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY SCREENING, 2018-2030 (USD MILLION)
• TABLE 342. SWITZERLAND LATENT TB TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 343. TURKEY LATENT TB TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 344. TURKEY LATENT TB TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 345. TURK

The Latent TB Testing Market was valued at USD 1.32 billion in 2024 and is projected to grow to USD 1.39 billion in 2025, with a CAGR of 5.70%, reaching USD 1.84 billion by 2030.

In today's rapidly evolving healthcare environment, the critical need for innovation in diagnostic solutions has become unmistakable. Latent TB testing stands at the forefront of efforts to combat tuberculosis by enabling early identification and timely intervention. This report provides an in-depth overview of the latent TB testing market, drawing attention to its importance in public health and clinical practice. Over recent years, heightened awareness of TB's latent forms coupled with advances in diagnostic technologies has reshaped how healthcare professionals approach detection and management. With precise and efficient testing methods emerging, the market is witnessing a shift from traditional techniques to more sophisticated assays that promise higher accuracy and faster turnaround times.

This comprehensive analysis explores the market drivers and challenges, the integration of emerging technologies, and the evolving regulatory frameworks guiding the industry. The discussion covers critical industry shifts and segmentation insights, offering a panoramic view of the current market landscape. By delving into application areas, test innovations, and regional variances, the narrative aims to present an engaging and authoritative perspective for decision-makers and experts alike.

Transformative Shifts Redefining the Market Landscape

The latent TB testing market is undergoing a transformative evolution driven by technological advancement, heightened regulatory scrutiny, and rapidly shifting clinician expectations. Developments in assay techniques such as the Interferon Gamma Release Assays and Tuberculin Skin Tests are catalyzing change, ensuring tests are not only more sensitive and specific, but also more streamlined and accessible. Innovations in automation, digital data integration, and sample processing are enhancing operational efficiencies and reducing turnaround times, thereby enabling laboratories to handle higher volumes with consistent accuracy.

Moreover, changes in patient demographics and an increased focus on preventive healthcare strategies are further influencing market priorities. Stakeholders are now compelled to adopt solutions that integrate seamlessly into existing diagnostic workflows while providing robust support for clinical decisions. Policy reforms and international health initiatives are also playing an integral role in shaping market dynamics, pushing the adoption of novel testing methodologies. This period of transformation is marked by an integration of research-driven insights with real-world clinical practice, thereby ensuring that the benefits of advanced diagnostics reach a broader spectrum of the population. In summary, the latent TB testing landscape is being reshaped through a blend of innovation, strategic investment, and a deep understanding of evolving healthcare imperatives.

Key Segmentation Insights from a Comprehensive Analysis

A granular view of the latent TB testing market reveals a multi-layered segmentation that is critical to understanding its multifaceted dynamics. The market is analyzed through several prisms: by product type, test type, application, and end user. When considering the product type, the market is studied across instruments, kits, and reagents, each catering to distinct operational needs and performance metrics. Delving into the test type, the analysis differentiates between Interferon Gamma Release Assays and the Tuberculin Skin Test. Notably, the Interferon Gamma Release Assays segment is further dissected into technologies such as chemiluminescence and ELISA, while the Tuberculin Skin Test is categorized into intradermal and multipuncture methods.

The application segmentation offers further insights, highlighting how the market is tailored for diagnostic testing, research, and screening purposes. Research itself subdivides into new test development and vaccine development, emphasizing the dual role of innovation and validation. Screening applications are nuanced by the requirements for routine health check-ups as well as immigration screening processes that target a diverse demographic landscape. Finally, the end user segmentation captures the market dynamics within diagnostic centres, hospital laboratories, public health departments, and research institutes. These segments together provide a detailed map of the industry, enabling stakeholders to pinpoint opportunities and tailor products to emerging needs with a precise understanding of each segment's operational nuances.

Based on Product Type, market is studied across Instruments, Kits, and Reagents.

Based on Test Type, market is studied across Interferon Gamma Release Assays (IGRAs) and Tuberculin Skin Test (TST). The Interferon Gamma Release Assays (IGRAs) is further studied across Chemiluminescence and ELISA (Enzyme-Linked Immunosorbent Assay). The Tuberculin Skin Test (TST) is further studied across Intradermal and Multipuncture.

Based on Application, market is studied across Diagnostic Testing, Research, and Screening. The Research is further studied across New Test Development and Vaccine Development. The Screening is further studied across Health Check-Ups and Immigration Screening.

Based on End User, market is studied across Diagnostic Centres, Hospital Laboratories, Public Health Departments, and Research Institutes.

Critical Regional Insights Offering a Global Perspective

The global landscape for latent TB testing is defined by distinct regional dynamics that mirror varying healthcare priorities, economic conditions, and regulatory environments. In the Americas, robust healthcare infrastructure paired with progressive adoption of advanced diagnostics fosters an environment where early detection is not just a clinical imperative, but also a significant driver of market growth. The region benefits from strong public-private partnerships and well-funded research institutions that champion the integration of high-end diagnostic assays.

Across Europe, the Middle East, and Africa, policy-driven initiatives and public health campaigns are instrumental in sustaining the momentum of early TB detection. Regulatory bodies in these regions ensure that advanced testing solutions complement national health strategies, particularly in areas with high disease prevalence and variable resource availability. In contrast, the Asia-Pacific region emerges as a vibrant hub powered by rapid technological adaptation and a burgeoning population that increasingly demands improved healthcare delivery. Here, expanding economies and a strong foothold in research and development are paving the way for innovative diagnostic technologies. Such regional variations emphasize the importance of tailored strategies to meet unique market demands, ensuring that high-quality latent TB testing reaches all corners of the globe.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insights on Leading Players Shaping Market Dynamics

The competitive landscape in latent TB testing is marked by the presence of several key companies that are at the forefront of driving innovation and ensuring quality diagnostics. Leading enterprises like Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company (BD), and Bio-Rad Laboratories, Inc. are instrumental in setting industry benchmarks for accuracy and efficiency. Companies such as Biocare Medical, LLC and bioMerieux SA are renowned for integrating advanced technological solutions into standard diagnostic workflows. Furthermore, industry stalwarts like Cepheid, Inc., Danaher Corporation, DiaSorin S.p.A., and Eiken Chemical Co., Ltd. continuously refine testing protocols through research and development initiatives.

The market ecosystem is further enriched by contributions from ElitechGroup SAS by Bruker Company, F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, and Hologic, Inc., as well as Mabtech AB and Meridian Bioscience, Inc. Not to be overlooked, innovators such as Oxford Immunotec Limited by PerkinElmer, Inc., Qiagen N.V., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Tosoh Bioscience, Inc. are also making significant strides to expand diagnostic capabilities. Cumulatively, these companies foster an environment of healthy competition and technological innovation, thereby elevating the overall standard of latent TB testing worldwide.

The report delves into recent significant developments in the Latent TB Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Biocare Medical, LLC, bioMerieux SA, Cepheid, Inc., Danaher Corporation, DiaSorin S.p.A., Eiken Chemical Co., Ltd., ElitechGroup SAS by Bruker Company, F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Hologic, Inc., Mabtech AB, Meridian Bioscience, Inc., Oxford Immunotec Limited by PerkinElmer, Inc., Qiagen N.V., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Tosoh Bioscience, Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are positioned at a critical juncture where proactive measures and strategic foresight can significantly influence market success in the latent TB testing space. It is essential to harness advancements in assay technology and automation by investing in research-driven innovations that not only meet current demand but are also scalable for future applications. Collaborations between technology providers, clinical research organizations, and regulatory authorities should be actively pursued to streamline the development and validation of next-generation testing platforms.

Adopting a data-centric approach to monitoring market trends and patient outcomes will further aid in fine-tuning product offerings and optimizing cost structures. Leaders should consider leveraging digital transformation tools to improve laboratory efficiency, facilitate real-time data sharing, and enhance diagnostic accuracy. Additionally, enhancing training programs for laboratory professionals to stay abreast of novel testing methodologies will ensure that the talent pool is prepared to handle evolving diagnostic requirements.

Furthermore, geographical expansion strategies should be refined in line with regional market specifics, ensuring that tailored solutions address localized healthcare challenges. An interdisciplinary approach that fosters innovation across R&D, production, and clinical application segments will likely yield competitive advantages and endorse sustained market leadership.

Conclusion: Embracing the Future of Latent TB Testing

In summary, the latent TB testing market is characterized by its dynamic evolution and robust growth potential driven by technological innovations, strategic segmentation, and a global emphasis on early diagnosis. The market is witnessing transformative shifts that not only redefine diagnostic protocols but also expand the possibilities for integrating advanced testing methods into routine healthcare systems. Insights into product types, test methodologies, applications, and end user segmentation offer a clear roadmap for deploying robust diagnostic solutions effectively.

Moreover, regional differences underscore the importance of customized approaches that address specific healthcare needs and regulatory environments. The combined efforts of key industry players, whose continual innovation and commitment to quality are setting new standards in testing, further enhance the landscape. For leaders and decision-makers, the latent TB testing space offers a compelling opportunity to align technological advancements with public health imperatives. As the healthcare industry marches toward precision and efficiency, embracing the future of latent TB testing with a strategic, informed approach becomes all the more critical.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing penetration of latent TB testing in rural and underserved areas through mobile clinics
    • 5.1.1.2. Increasing prevalence of diseases that weaken the immune system increasing susceptibility to TB infection
    • 5.1.1.3. Rising awareness about latent tuberculosis infections among at-risk populations and healthcare providers
  • 5.1.2. Restraints
    • 5.1.2.1. Analyzing the impact of high costs and limited funding on latent TB testing accessibility and expansion
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in TB testing methods enhancing speed, accuracy, and accessibility
    • 5.1.3.2. Collaborations between public and private sectors strengthening the latent TB diagnostic market
  • 5.1.4. Challenges
    • 5.1.4.1. Inconsistent government policies and regulations across different countries or regions
• 5.2. Market Segmentation Analysis
  • 5.2.1. Test Type: Utilization in tuberculin skin testing for enhancing accuracy and accessibility
  • 5.2.2. End User: Adoption in latent TB testing for hospital laboratories due to advanced technologies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Latent TB Testing Market, by Product Type

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Kits
• 6.4. Reagents

7. Latent TB Testing Market, by Test Type

• 7.1. Introduction
• 7.2. Interferon Gamma Release Assays (IGRAs)
  • 7.2.1. Chemiluminescence
  • 7.2.2. ELISA (Enzyme-Linked Immunosorbent Assay)
• 7.3. Tuberculin Skin Test (TST)
  • 7.3.1. Intradermal
  • 7.3.2. Multipuncture

8. Latent TB Testing Market, by Application

• 8.1. Introduction
• 8.2. Diagnostic Testing
• 8.3. Research
  • 8.3.1. New Test Development
  • 8.3.2. Vaccine Development
• 8.4. Screening
  • 8.4.1. Health Check-Ups
  • 8.4.2. Immigration Screening

9. Latent TB Testing Market, by End User

• 9.1. Introduction
• 9.2. Diagnostic Centres
• 9.3. Hospital Laboratories
• 9.4. Public Health Departments
• 9.5. Research Institutes

10. Americas Latent TB Testing Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Latent TB Testing Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Latent TB Testing Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. FPNV Positioning Matrix, 2024
• 13.3. Competitive Scenario Analysis
  • 13.3.1. U.S. launch of SIMLANDI Teva and Alvotech's strategic biosimilar milestone
  • 13.3.2. Revvity introduces advanced automation in latent TB testing with auto-pure 2400
  • 13.3.3. QIAGEN enhances tuberculosis testing portfolio with new NGS panel for improved surveillance
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Beckman Coulter, Inc.
• 3. Becton, Dickinson and Company (BD)
• 4. Bio-Rad Laboratories, Inc.
• 5. Biocare Medical, LLC
• 6. bioMerieux SA
• 7. Cepheid, Inc.
• 8. Danaher Corporation
• 9. DiaSorin S.p.A.
• 10. Eiken Chemical Co., Ltd.
• 11. ElitechGroup SAS by Bruker Company
• 12. F. Hoffmann-La Roche AG
• 13. Fujifilm Holdings Corporation
• 14. Hologic, Inc.
• 15. Mabtech AB
• 16. Meridian Bioscience, Inc.
• 17. Oxford Immunotec Limited by PerkinElmer, Inc.
• 18. Qiagen N.V.
• 19. Siemens Healthineers AG
• 20. Thermo Fisher Scientific Inc.
• 21. Tosoh Bioscience, Inc.